Scientists have long known that the blood vessels of tumors differ markedly from normal blood vessels. Now, a research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC) has identified a signaling pathway which, when activated, transforms otherwise healthy blood vessels into the leaky, misshapen vasculature that characterizes cancerous tumors.
The findings, published in the August 2006 issue of Cancer Cell, additionally demonstrate that rapamycin, a compound used for immunosuppression in transplant patients and currently under investigation as a cancer treatment, can successfully block this signaling pathway--known as the Akt pathway-- in blood vessels. This discovery further enhances the drug's promise as a cancer therapy.
"There are three major hallmarks associated with tumor blood vessels," explains the study's senior author Laura Benjamin, PhD, an investigator in BIDMC's Department of Pathology and Associate Professor of Pathology at Harvard Medical School.
"First, unlike healthy blood vessels which are uniform in structure, a tumor's blood vessels balloon and narrow, forming a highly irregular shape. Second, the layer of smooth muscle that you would expect to find covering the blood vessels is inadequate, often resulting in only intermittent coverage. And last, a tumor's blood vessels are overly permeable or leaky."
The hypothesis that blood vessel formation in tumors is essential for the growth and spread of cancer was first proposed in the early 1970's, and in 1983, it was shown that tumors secrete a factor called VEGF (vascular endothelial growth factor) that induces the permeability associated with blood vessels in cancer.
In this new study, Benjamin and first author Thuy Phung, MD, PhD, of BIDMC's Department of Pathology, hypothesized that the Akt pathway was mediating many of the functions of VEGF in tumors, including the stimulation of blood vessels with abnormal structure and excessive leak. Using a mouse model that enabled them to activate the Akt pathway in healthy blood vessel cells – without the complicating influence of tumor cells – they observed that Akt-induced blood vessels demonstrated the very same abnormalities that are seen in tumor blood vessels. Moreover, adds Benjamin, "We discovered that simply removing the activated Akt was sufficient to reverse these vasculature changes."
The scientists then went on to treat the animals with rapamycin. As predicted, the agent blocked the Akt-induced blood vessel changes. In subsequent experiments, rapamycin reduced tumor growth and vascular leak in a mouse tumor model.
"This paper represents an impressive advance in our understanding of the mechanisms by which tumors generate the new blood vessels they need to survive and grow," says Harold Dvorak, MD, Director of the Vascular Biology Center at BIDMC and Mallinckrodt Professor of Pathology Emeritus at Harvard Medical School, in whose laboratory VEGF was first discovered 23 years ago. "This suggests an attractive new molecular target for cancer therapy."
Approved by the U.S. Food and Drug Administration (FDA) as an immunosuppressant agent, rapamycin is being tested in clinical trials as a cancer treatment.
"These new findings suggest that we should think about using rapamycin in regimens where anti-angiogenic therapy in cancer patients is desired," says Benjamin. "If human tumors respond in the same way that animal models have, rapamycin may normalize and diminish the tumor vasculature, and this is particularly exciting because these findings are clinically relevant today."
In addition to Benjamin and Phung, study coauthors include BIDMC investigators Donnette Dabydeen, BS, Godfred Eyiah-Mensah, BA, Marcela Riveros, MD, Carole Perruzzi, BA, Jingfang Sun, DVM, Rita Monahan-Earley, BA, Janice Nagy, PhD, Ann Dvorak, MD, and Harold F. Dvorak, MD; Keren Ziv, MS, and Michal Neeman, PhD, of the Weizmann Institute of Science in Israel; Ichiro Shiojima, MD, PhD, and Kenneth Walsh, PhD, of Boston University School of Medicine; Michelle Lin, PhD, and William Sessa PhD, of Yale University School of Medicine, New Haven, Connecticut; and David Briscoe, MD, of Children's Hospital, Boston.
Bonnie Prescott | EurekAlert!
How brains surrender to sleep
23.06.2017 | IMP - Forschungsinstitut für Molekulare Pathologie GmbH
A new technique isolates neuronal activity during memory consolidation
22.06.2017 | Spanish National Research Council (CSIC)
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology